Table of Contents
Molecular Biology International
Volume 2012, Article ID 849874, 8 pages
http://dx.doi.org/10.1155/2012/849874
Review Article

Pathogenetic and Prognostic Significance of Inactivation of RASSF Proteins in Human Hepatocellular Carcinoma

Institut für Pathologie, Universitätsmedizin Greifswald, 17489 Greifswald, Germany

Received 29 November 2011; Accepted 26 January 2012

Academic Editor: Dae-Sik Lim

Copyright © 2012 Diego F. Calvisi et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. J. Bruix, L. Boix, M. Sala, and J. M. Llovet, “Focus on hepatocellular carcinoma,” Cancer Cell, vol. 5, no. 3, pp. 215–219, 2004. View at Publisher · View at Google Scholar · View at Scopus
  2. H. B. El-Serag and K. L. Rudolph, “Hepatocellular carcinoma: epidemiology and molecular carcinogenesis,” Gastroenterology, vol. 132, no. 7, pp. 2557–2576, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  3. J. M. Llovet, A. Burroughs, and J. Bruix, “Hepatocellular carcinoma,” The Lancet, vol. 362, no. 9399, pp. 1907–1917, 2003. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  4. H. C. Spangenberg, R. Thimme, and H. E. Blum, “Targeted therapy for hepatocellular carcinoma,” Nature Reviews Gastroenterology and Hepatology, vol. 6, no. 7, pp. 423–432, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  5. S. S. Thorgeirsson and J. W. Grisham, “Molecular pathogenesis of human hepatocellular carcinoma,” Nature Genetics, vol. 31, no. 4, pp. 339–346, 2002. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  6. D. F. Calvisi, S. Ladu, A. Gorden et al., “Ubiquitous activation of Ras and Jak/stat pathways in human HCC,” Gastroenterology, vol. 130, no. 4, pp. 1117–1128, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  7. M. Barbacid, “ras oncogenes: their role in neoplasia,” European Journal of Clinical Investigation, vol. 20, no. 3, pp. 225–235, 1990. View at Google Scholar · View at Scopus
  8. S. Schubbert, K. Shannon, and G. Bollag, “Hyperactive Ras in developmental disorders and cancer,” Nature Reviews Cancer, vol. 7, no. 4, pp. 295–308, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  9. D. F. Calvisi, F. Pinna, F. Meloni et al., “Dual-specificity phosphatase 1 ubiquitination in extracellular signal-regulated kinase-mediated control of growth in human hepatocellular carcinoma,” Cancer Research, vol. 68, no. 11, pp. 4192–4200, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  10. D. F. Calvisi, S. Ladu, E. A. Conner et al., “Inactivation of Ras GTPase-activating proteins promotes unrestrained activity of wild-type Ras in human liver cancer,” Journal of Hepatology, vol. 54, no. 2, pp. 311–319, 2011. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  11. R. Dammann, U. Schagdarsurengin, C. Seidel et al., “The tumor suppressor RASSF1A in human carcinogenesis: an update,” Histology and Histopathology, vol. 20, no. 2, pp. 645–663, 2005. View at Google Scholar · View at Scopus
  12. L. van der Weyden and D. J. Adams, “The Ras-association domain family (RASSF) members and their role in human tumourigenesis,” Biochimica et Biophysica Acta, vol. 1776, no. 1, pp. 58–85, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  13. A. M. Richter, G. P. Pfeifer, and R. H. Dammann, “The RASSF proteins in cancer; from epigenetic silencing to functional characterization,” Biochimica et Biophysica Acta, vol. 1796, no. 2, pp. 114–128, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  14. J. Avruch, R. Xavier, N. Bardeesy et al., “Rassf family of tumor suppressor polypeptides,” Journal of Biological Chemistry, vol. 284, no. 17, pp. 11001–11005, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  15. M. Gordon and S. Baksh, “RASSF1A: not a prototypical Ras effector,” Small GTPases, vol. 2, no. 3, pp. 148–157, 2011. View at Publisher · View at Google Scholar · View at PubMed
  16. Y. J. Zhang, H. Ahsan, Y. Chen et al., “High frequency of promoter hypermethylation of RASSF1A and p16 and its relationship to aflatoxin B1-DNA adduct levels in human hepatocellular carcinoma,” Molecular Carcinogenesis, vol. 35, no. 2, pp. 85–92, 2002. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  17. J. Yu, M. Ni, J. Xu et al., “Methylation profiling of twenty promoter-CpG islands of genes which may contribute to hepatocellular carcinogenesis,” BMC Cancer, vol. 2, no. 1, p. 29, 2002. View at Google Scholar · View at Scopus
  18. S. Zhong, W. Yeo, M. W. Tang, N. Wong, P. B. S. Lai, and P. J. Johnson, “Intensive hypermethylation of the CpG island of Ras association domain family 1A in hepatitis B virus-associated hepatocellular carcinomas,” Clinical Cancer Research, vol. 9, no. 9, pp. 3376–3382, 2003. View at Google Scholar · View at Scopus
  19. S. Lee, H. J. Lee, J. H. Kim, H. S. Lee, J. J. Jang, and G. H. Kang, “Aberrant CpG island hypermethylation along multistep hepatocarcinogenesis,” American Journal of Pathology, vol. 163, no. 4, pp. 1371–1378, 2003. View at Google Scholar · View at Scopus
  20. U. Lehmann, I. Berg-Ribbe, L. U. Wingen et al., “Distinct methylation patterns of benign and malignant livertumors revealed by quantitative methylation profiling,” Clinical Cancer Research, vol. 11, no. 10, pp. 3654–3660, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  21. S. di Gioia, P. Bianchi, A. Destro et al., “Quantitative evaluation of RASSF1A methylation in the non-lesional, regenerative and neoplastic liver,” BMC Cancer, vol. 6, p. 89, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  22. N. Nishida, T. Nagasaka, T. Nishimura, I. Ikai, C. R. Boland, and A. Goel, “Aberrant methylation of multiple tumor suppressor genes in aging liver, chronic hepatitis, and hepatocellular carcinoma,” Hepatology, vol. 47, no. 3, pp. 908–918, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  23. U. Schagdarsurengin, L. Wilkens, D. Steinemann et al., “Frequent epigenetic inactivation of the RASSF1A gene in hepatocellular carcinoma,” Oncogene, vol. 22, no. 12, pp. 1866–1871, 2003. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  24. L. Hu, G. Chen, H. Yu, and X. Qiu, “Clinicopathological significance of RASSF1A reduced expression and hypermethylation in hepatocellular carcinoma,” Hepatology International, vol. 4, no. 1, pp. 423–432, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  25. D. F. Calvisi, S. Ladu, A. Gorden et al., “Mechanistic and prognostic significance of aberrant methylation in the molecular pathogenesis of human hepatocellular carcinoma,” Journal of Clinical Investigation, vol. 117, no. 9, pp. 2713–2722, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  26. J. Ren, W. He, R. Zhang et al., “RASSF2A promoter methylation in hepatitis B virus-related hepatocellular carcinogenesis and its correlation with elevated serum α-fetoprotein level,” Journal of Huazhong University of Science and Technology-Medical Science, vol. 29, no. 3, pp. 309–312, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  27. D. Macheiner, G. Heller, S. Kappel et al., “NORE1B, a candidate tumor suppressor, is epigenetically silenced in human hepatocellular carcinoma,” Journal of Hepatology, vol. 45, no. 1, pp. 81–89, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  28. R. Dammann, C. Li, J. H. Yoon, P. L. Chin, S. Bates, and G. P. Pfeifer, “Epigenetic inactivation of a RAS association domain family protein from the lung tumour suppressor locus 3p21.3,” Nature Genetics, vol. 25, no. 3, pp. 315–319, 2000. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  29. H. Su, J. Zhao, Y. Xiong et al., “Large-scale analysis of the genetic and epigenetic alterations in hepatocellular carcinoma from Southeast China,” Mutation Research, vol. 641, no. 1-2, pp. 27–35, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  30. U. Lehmann, L. U. Wingen, K. Brakensiek et al., “Epigenetic defects of hepatocellular carcinoma are already found in non-neoplastic liver cells from patients with hereditary haemochromatosis,” Human Molecular Genetics, vol. 16, no. 11, pp. 1335–1342, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  31. M. Strunnikova, U. Schagdarsurengin, A. Kehlen, J. C. Garbe, M. R. Stampfer, and R. Dammann, “Chromatin inactivation precedes de novo DNA methylation during the progressive epigenetic silencing of the RASSF1A promoter,” Molecular and Cellular Biology, vol. 25, no. 10, pp. 3923–3933, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  32. Y. Kondo, L. Shen, S. Suzuki et al., “Alterations of DNA methylation and histone modifications contribute to gene silencing in hepatocellular carcinomas,” Hepatology Research, vol. 37, no. 11, pp. 974–983, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  33. I. Tischoff, A. Markwarth, H. Witzigmann et al., “Allele loss and epigenetic inactivation of 3p21.3 in malignant liver tumors,” International Journal of Cancer, vol. 115, no. 5, pp. 684–689, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  34. B. Bressac, M. Kew, J. Wands, and M. Ozturk, “Selective G to T mutations of p53 gene in hepatocellular carcinoma from southern Africa,” Nature, vol. 350, no. 6317, pp. 429–431, 1991. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  35. I. C. Hsu, R. A. Metcalf, T. Sun, J. A. Welsh, N. J. Wang, and C. C. Harris, “Mutational hotspot in the p53 gene in human hepatocellular carcinomas,” Nature, vol. 350, no. 6317, pp. 427–428, 1991. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  36. L. Yang, Z. Ma, D. Wang, W. Zhao, L. Chen, and G. Wang, “MicroRNA-602 regulating tumor suppressive gene RASSF1A is overexpressed in hepatitis B virus-infected liver and hepatocellular carcinoma,” Cancer Biology and Therapy, vol. 9, no. 10, pp. 801–806, 2010. View at Google Scholar · View at Scopus
  37. M. S. Song, S. J. Song, S. J. Kim, K. Nakayama, K. I. Nakayama, and D. S. Lim, “Skp2 regulates the antiproliferative function of the tumor suppressor RASSF1A via ubiquitin-mediated degradation at the G1-S transition,” Oncogene, vol. 27, no. 22, pp. 3176–3185, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  38. D. F. Calvisi, S. Ladu, F. Pinna et al., “SKP2 and CKS1 promote degradation of cell cycle regulators and are associated with hepatocellular carcinoma prognosis,” Gastroenterology, vol. 137, no. 5, pp. 1816–e10, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  39. S. Rabizadeh, R. J. Xavier, K. Ishiguro et al., “The scaffold protein CNK1 interacts with the tumor suppressor RASSF1A and augments RASSF1A-induced cell death,” Journal of Biological Chemistry, vol. 279, no. 28, pp. 29247–29254, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  40. A. Khokhlatchev, S. Rabizadeh, R. Xavier et al., “Identification of a novel Ras-regulated proapoptotic pathway,” Current Biology, vol. 12, no. 4, pp. 253–265, 2002. View at Publisher · View at Google Scholar · View at Scopus
  41. G. Halder and R. L. Johnson, “Hippo signaling: growth control and beyond,” Development, vol. 138, no. 1, pp. 9–22, 2011. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  42. B. Zhao, K. Tumaneng, and K.-L. Guan, “The Hippo pathway in organ size control, tissue regeneration and stem cell self-renewal,” Nature Cell Biology, vol. 13, no. 8, pp. 877–883, 2011. View at Publisher · View at Google Scholar · View at PubMed
  43. Q. Zeng and W. Hong, “The emerging role of the hippo pathway in cell contact inhibition, organ size control, and cancer development in mammals,” Cancer Cell, vol. 13, no. 3, pp. 188–192, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  44. S. W. Chan, C. J. Lim, L. Chen et al., “The hippo pathway in biological control and cancer development,” Journal of Cellular Physiology, vol. 226, no. 4, pp. 928–939, 2011. View at Publisher · View at Google Scholar · View at PubMed
  45. K. P. Lee, J. H. Lee, T. S. Kim et al., “The Hippo-Salvador pathway restrains hepatic oval cell proliferation, liver size, and liver tumorigenesis,” Proceedings of the National Academy of Sciences of the United States of America, vol. 107, no. 18, pp. 8248–8253, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  46. D. Zhou, C. Conrad, F. Xia et al., “Mst1 and Mst2 maintain hepatocyte quiescence andsuppress hepatocellular carcinoma development through inactivation of the yap1 oncogene,” Cancer Cell, vol. 16, no. 5, pp. 425–438, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  47. L. Lu, Y. Li, S. M. Kim et al., “Hippo signaling is a potent in vivo growth and tumor suppressor pathway in the mammalian liver,” Proceedings of the National Academy of Sciences of the United States of America, vol. 107, no. 4, pp. 1437–1442, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  48. H. Song, K. K. Mak, L. Topol et al., “Mammalian Mst1 and Mst2 kinases play essential roles in organ size control and tumor suppression,” Proceedings of the National Academy of Sciences of the United States of America, vol. 107, no. 4, pp. 1431–1436, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  49. F. D. Camargo, S. Gokhale, J. B. Johnnidis et al., “YAP1 increases organ size and expands undifferentiated progenitor cells,” Current Biology, vol. 17, no. 23, pp. 2054–2060, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  50. J. Dong, G. Feldmann, J. Huang et al., “Elucidation of a universal size-control mechanism in drosophila and mammals,” Cell, vol. 130, no. 6, pp. 1120–1133, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  51. C. Guo, X. Zhang, and G. P. Pfeifer, “The tumor suppressor RASSF1A prevents dephosphorylation of the mammalian STE20-like kinases MST1 and MST2,” Journal of Biological Chemistry, vol. 286, no. 8, pp. 6253–6261, 2011. View at Publisher · View at Google Scholar · View at PubMed
  52. W. J. Xue, C. Li, X. J. Zhou et al., “RASSF1A expression inhibits the growth of hepatocellular carcinoma from Qidong County,” Journal of Gastroenterology and Hepatology, vol. 23, no. 9, pp. 1448–1458, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  53. M. D. Vos, A. Dallol, K. Eckfeld et al., “The RASSF1A tumor suppressor activates bax via MOAP-1,” Journal of Biological Chemistry, vol. 281, no. 8, pp. 4557–4563, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  54. D. F. Calvisi, H. Donninger, M. D. Vos et al., “NORE1A tumor suppressor candidate modulates p21CIP1 via p53,” Cancer Research, vol. 69, no. 11, pp. 4629–4637, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  55. G. J. Browne, S. G. Finn, and C. G. Proud, “Stimulation of the AMP-activated protein kinase leads to activation of eukaryotic elongation factor 2 kinase and to its phosphorylation at a novel site, serine 398,” Journal of Biological Chemistry, vol. 279, no. 13, pp. 12220–12231, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  56. E. Connolly, S. Braunstein, S. Formenti, and R. J. Schneider, “Hypoxia inhibits protein synthesis through a 4E-BP1 and elongation factor 2 kinase pathway controlled by mTOR and uncoupled in breast cancer cells,” Molecular and Cellular Biology, vol. 26, no. 10, pp. 3955–3965, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  57. A. E. Pegg, “Spermidine/spermine-N(1)-acetyltransferase: a key metabolic regulator,” American Journal of Physiology-Endocrinology and Metabolism, vol. 294, no. 6, pp. 995–1010, 2008. View at Google Scholar
  58. E. W. Gerner and F. L. Meyskens, “Polyamines and cancer: old molecules, new understanding,” Nature Reviews Cancer, vol. 4, no. 10, pp. 781–792, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  59. A. Agathanggelou, I. Bièche, J. Ahmed-Choudhury et al., “Identification of novel gene expression targets for the ras association domain family 1 (RASSF1A) tumor suppressor gene in non-small cell lung cancer and neuroblastoma,” Cancer Research, vol. 63, no. 17, pp. 5344–5351, 2003. View at Google Scholar · View at Scopus
  60. Y. H. Ou, P. H. Chung, F. F. Hsu, T. P. Sun, W. Y. Chang, and S. Y. Shieh, “The candidate tumor suppressor BTG3 is a transcriptional target of p53 that inhibits E2F1,” EMBO Journal, vol. 26, no. 17, pp. 3968–3980, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  61. B. W. Baron, N. Zeleznik-Le, M. J. Baron et al., “Repression of the PDCD2 gene by BCL6 and the implications for the pathogenesis of human B and T cell lymphomas,” Proceedings of the National Academy of Sciences of the United States of America, vol. 104, no. 18, pp. 7449–7454, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  62. Y. Aoyama, J. Avruch, and X. F. Zhang, “Nore1 inhibits tumor cell growth independent of Ras or the MST1/2 kinases,” Oncogene, vol. 23, no. 19, pp. 3426–3433, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  63. W. C. Weinberg and M. F. Denning, “P21WAF1 control of epithelial cell cycle and cell fate,” Critical Reviews in Oral Biology and Medicine, vol. 13, no. 6, pp. 453–464, 2002. View at Google Scholar · View at Scopus
  64. D. Macheiner, C. Gauglhofer, C. Rodgarkia-Dara et al., “NORE1B is a putative tumor suppressor in hepatocarcinogenesis and may act via RASSF1A,” Cancer Research, vol. 69, no. 1, pp. 235–242, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  65. K. Shimizu, M. Onishi, E. Sugata et al., “Disturbance of DNA methylation patterns in the early phase of hepatocarcinogenesis induced by a choline-deficient L-amino acid-defined diet in rats,” Cancer Science, vol. 98, no. 9, pp. 1318–1322, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  66. D. F. Calvisi, F. Pinna, S. Ladu et al., “The degradation of cell cycle regulators by SKP2/CKS1 ubiquitin ligase is genetically controlled in rodent liver cancer and contributes to determine the susceptibility to the disease,” International Journal of Cancer, vol. 126, no. 5, pp. 1275–1281, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  67. D. F. Calvisi, F. Pinna, R. Pellegrino et al., “Ras-driven proliferation and apoptosis signaling during rat liver carcinogenesis is under genetic control,” International Journal of Cancer, vol. 123, no. 9, pp. 2057–2064, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  68. I. P. Pogribny, L. Muskhelishvili, V. P. Tryndyak, and F. A. Beland, “The role of epigenetic events in genotoxic hepatocarcinogenesis induced by 2-acetylaminofluorene,” Mutation Research, vol. 722, no. 2, pp. 106–113, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  69. S. Tommasi, R. Dammann, Z. Zhang et al., “Tumor susceptibility of RASSF1A knockout mice,” Cancer Research, vol. 65, no. 1, pp. 92–98, 2005. View at Google Scholar · View at Scopus
  70. S. A. Lee, S. Ladu, M. Evert et al., “Synergistic role of sprouty2 inactivation and c-Met up-regulation in mouse and human hepatocarcinogenesis,” Hepatology, vol. 52, no. 2, pp. 506–517, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  71. N. Underhill-Day, V. Hill, and F. Latif, “N-terminal RASSF family (RASSF7-RASSF10): a mini review,” Epigenetics, vol. 6, no. 3, pp. 284–292, 2011. View at Publisher · View at Google Scholar